In this MasterClass, Drs. Douglas K. Devries and Marc Bloomenstein discuss the role and impact of ocular surface disease (OSD) on patient satisfaction. They define dry eye disease (DED), its prevalence, and its affect on cataract surgery outcomes.
Supported by unrestricted educational grants from Alcon Vision, Avellino Labs, Bausch + Lomb, Johnson & Johnson Vision, RVL Pharmaceuticals, Santen, Sight Sciences, Tarsus, TearLab, and Thea.
Upon completion of this activity, the participant should be able to:
Sponsored by:
This activity, COPE Activity Number 123294, is accredited by COPE for continuing education for optometrists.
This course is approved for .25 hours CE.
Evolve Medical Education, LLC is a COPE accredited administrator.
Course ID: 76600-TD
Activity ID: 123294
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Marc Bloomenstein, OD, FAAO
Schwartz Laser Eye Center
Director of Optometric Services
Scottsdale, AZ
Douglas K. Devries, OD
Co-Founder
Eye Care Associates of Nevada
Sparks, NV
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Marc Bloomenstein, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Bausch + Lomb, BioTissue, Johnson & Johnson Vision, Kala Pharmaceuticals, Ocusoft, Reichert, and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, and Sun.
Douglas K. Devries, OD, has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Advisory Board: Akorn, Alcon, Allergan, Avelino, Azura, Bausch + Lomb, BlephEx, Bio Tissue, Bruder, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, OcuSoft, Quidel, Sight Sciences, Science Based Health, Sun Pharmaceutical Industries, Tarsus, Tearlab, Thea, and Visus. Speaker’s Bureau: Allergan, Bausch + Lomb, Bio Tissue, BlephEx, Bruder, Eyevance, Kala Pharmaceuticals, Lumenis, Johnson & Johnson Vision, OcuSoft, Sight Sciences, Science Based Health, Sun Pharmaceutical Industries, and Tearlab. Stock/Shareholder: RPS.
The Evolve, reviewers, and The Fundingsland Group planners have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Alcon Vision, Avellino Labs, Bausch + Lomb, Johnson & Johnson Vision, RVL Pharmaceuticals, Santen, Sight Sciences, Tarsus, TearLab, or Thea.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
Douglas K. Devries, OD
Cecelia Koetting, OD, FAAO
